logo

Last Update

This profile was last updated on 8/14/2017 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Anthony Cmelak?

Anthony J. Cmelak

Professor, Senior Medical Director

Vanderbilt University

HQ Phone:  (615) 322-5000

Direct Phone: (615) ***-****direct phone

Email: a***@***.edu

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Vanderbilt University

2220 Pierce Ave 771 Prb

Nashville, Tennessee,37232

United States

Company Description

Vanderbilt University is a private, nonsectarian, coeducational research university in Nashville, Tennessee, USA. Founded in 1873, the university is named for shipping and rail magnate "Commodore" Cornelius Vanderbilt, who provided Vanderbilt its initial $1 mi...more

Background Information

Employment History

Professor, Senior Medical Director

Radiation Oncology Centres


Affiliations

American Society of Clinical Oncology

Head and Neck Cancer Track Leader for the Annual Meeting


American Society for Therapeutic Radiology and Oncology

Member


Society for Neuro-Oncology

Member


American Society of Otolaryngology - Head and Neck Surgery

Member


National Comprehensive Cancer Network

Member


Education

M.D.


Web References(48 Total References)


Vanderbilt Corporate Relations - A to Z Directory - Vanderbilt Health Nashville, TN

vanderbilthealth.com [cached]

Anthony Joseph Cmelak


cetuximab - Page 2 - Oral Cancer News

oralcancernews.org [cached]

The research was presented by lead author Anthony Cmelak, M.D., professor of Radiation Oncology at Vanderbilt-Ingram Cancer Center, during the 50th annual meeting of the American Society of Clinical Oncology (ASCO), held May 30 to June 3 in Chicago.
"Treatment for head and neck cancer can be quite grueling, so it's very encouraging to see we can safely dial back treatment for patients with less aggressive disease and an overall good prognosis, particularly for young patients who have many years to deal with long-term side effects," said Cmelak. He noted that lower-dose IMRT is not recommended for patients with HPV-negative cancer or larger tumors. Two-year overall survival and progression-free survival were 93% and 80%, respectively, among 62 patients with operable stage III/IVA HPV-positive oropharyngeal squamous carcinoma who received lower-dose intensity-modulated radiation therapy (IMRT) after clinical complete response to induction chemotherapy, reported Dr. Anthony Cmelak, professor of radiation oncology at Vanderbilt University, Nashville, Tenn., and medical director of the Vanderbilt-Ingram Cancer Center at Franklin. However, Dr. Cmelak does not yet recommend modifying regimens for patients with HPV-positive disease. "I don't recommend using lower doses now, off study. Ultimately, we will need a large randomized trial," he said. "This study represents one more piece of evidence that we need to look at the optimal regimen for both chemotherapy and radiation technique and dosage to minimize toxicities," he added.


NobleResearch

www.nobleresearch.org [cached]

Dr. Anthony Cmelak, Professor,
Senior Medical Director, Vanderbilt Department of Radiation Oncology, Dr. Anthony Cmelak is Professor in the Department of Radiation Oncology and Senior Medical Director. He is also director of satellite facilities, including the Vanderbilt-Ingram Cancer Center at Franklin (VICCAF), the Gateway-Vanderbilt Cancer Center (GVCTC) in Clarksville, Tennessee, and the Vanderbilt-Murray Radiation Oncology Center (VMRO) in Spring Hill, Tennessee. Dr. Cmelak is the Department's Principal Investigator for cancers of the head and neck, and is also the director of the stereotactic radiosurgery program for the treatment of both intracranial and extracranial neoplasms. He is Vanderbilt's Primary Investigator in Radiation Therapy Oncology Group (RTOG) clinical trials, and is a Core Committee member for head and neck cancers in the Eastern Cooperative Oncology Group (ECOG), where he has chaired or co-chaired a number of multi-institutional studies. He is a member of the American Society Of Therapeutic Radiology and Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), the Society for Neuro-Oncology (SNO), and the American Society of Otolaryngology-Head and Neck Surgery where he has presented results from a number of research studies. He is the head and neck cancer Track Leader for the annual meeting for the American Society of Clinical Oncology (ASCO) for the past 2 years, and is a member of the Head and Neck Committee for the National Comprehensive Cancer Network (NCCN).


cisplatin - Oral Cancer News

oralcancernews.org [cached]

Two-year overall survival and progression-free survival were 93% and 80%, respectively, among 62 patients with operable stage III/IVA HPV-positive oropharyngeal squamous carcinoma who received lower-dose intensity-modulated radiation therapy (IMRT) after clinical complete response to induction chemotherapy, reported Dr. Anthony Cmelak, professor of radiation oncology at Vanderbilt University, Nashville, Tenn., and medical director of the Vanderbilt-Ingram Cancer Center at Franklin.
However, Dr. Cmelak does not yet recommend modifying regimens for patients with HPV-positive disease. "I don't recommend using lower doses now, off study. Ultimately, we will need a large randomized trial," he said. "This study represents one more piece of evidence that we need to look at the optimal regimen for both chemotherapy and radiation technique and dosage to minimize toxicities," he added.


human papilloma virus - Page 3 - Oral Cancer News

oralcancernews.org [cached]

Author: Anthony Cmelak, M.D. Source: medicalnewstoday.com
A new study suggests that lowering the dose of radiation therapy for some head and neck cancer patients may improve outcomes and cause fewer long-term side effects. The research was presented by lead author Anthony Cmelak, M.D., professor of Radiation Oncology at Vanderbilt-Ingram Cancer Center (VICC), during the 50th annual meeting of the American Society of Clinical Oncology (ASCO), held recently in Chicago. The study focused on patients with newly-diagnosed oropharyngeal cancers related to the human papilloma virus (HPV). More than two-thirds of new head and neck cancer patients have HPV-positive tumors and the number of these patients is on the rise. Cmelak's prior cooperative group study found that patients with HPV-positive oropharyngeal cancer have significantly longer survival rates than patients whose tumors are HPV negative. "Treatment for head and neck cancer can be quite grueling, so it's very encouraging to see we can safely dial back treatment for patients with less aggressive disease and an overall good prognosis, particularly for young patients who have many years to deal with long-term side effects," said Cmelak. He noted that lower-dose IMRT is not recommended for patients with HPV-negative cancer or larger tumors.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory